RECARDIO
Recardio is a life science company that focuses on drug-based regenerative therapeutic modalities for treatments of cardiovascular diseases.
RECARDIO
Industry:
Health Care Life Science Medical
Founded:
2011-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.recardio.eu
Total Employee:
51+
Status:
Active
Total Funding:
3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Wordpress Plugins Nginx Microsoft Exchange Online
Similar Organizations
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Current Employees Featured
Founder
Official Site Inspections
http://www.recardio.eu
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Recardio"
Recardio - Crunchbase Company Profile & Funding
Contact Email [email protected] Recardio is a clinical-stage life science business focused on cardiovascular, cancer, and infectious disease medicines. The …See details»
Recardio 2025 Company Profile: Valuation, Funding & Investors
Recardio General Information Description. Developer of a regenerative medicine company designed to advance therapies for cardiovascular diseases. The company platform offers a …See details»
Background - recardio.eu
Recardio. Regenerative Cardiac. About Us. Profile; Management; Boards; Awards; Science. Approach; Background; Therapy; Clinical. Phase 1; Phase 2B AMI; PHASE 3 (HEAL-AMI) …See details»
Recardio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Recardio, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 4 news, and 3 literature, Technology Platform:Small molecule drug, Drug:Dutogliptin Tartrate, …See details»
Recardio’s Competitors, Revenue, Number of Employees, Funding …
Recardio’s Profile, Revenue and Employees. Recardio is a clinical-stage life science company focusing on drug based regenerative therapies for the treatment of cardiovascular diseases.See details»
Recardio GmbH - Life Sciences Directory
Recardio GmbH Back to list. Facts. Founded 2011 Staff 5 Organization type RDM biotech/pharma Region ... Organization type RDM biotech/pharma Region Lower Austria Cluster ecoplus ...See details»
Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design
Jun 1, 2022 Recardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with …See details»
Recardio - VentureRadar
RECARDIO (REgenerative CARDIOvascular Therapy) is a clinical-stage life science company focusing on therapies for cardiovascular, oncology and infectious diseases. The company is …See details»
Recardio - Overview, News & Similar companies | ZoomInfo.com
May 22, 2022 Who is Recardio. Recardio Inc. is a clinical-stage life science company focusing on therapies for cardiovascular and other diseases. The company is located in San F rancisco, …See details»
Kancera » Kancera signs letter of intent agreement with Recardio …
Mar 7, 2025 For more information, visit: www.recardio.eu or contact [email protected] This information is information that Kancera is obliged to make public pursuant to the EU Market …See details»
Closings of Series C Financing Round - recardio.eu
May 31, 2023 About Recardio. Recardio Inc. is a late-stage clinical life science company focusing on therapies for cardiovascular and other diseases. The company is located in San …See details»
What is the Website Location of Recardio.eu? - IP-Tracker.org
Recardio.eu - Hostname: 246.145.214.35.bc.googleusercontent.com, ISP/Organization: GOOGLE, Website Address Location: Groningen Groningen Netherlands ... Our tracking …See details»
Recardio's Digital Platform, CardioCare, Rolled Out in Europe - PR …
Nov 6, 2019 Recardio's Digital Platform CardioCare was awarded and presented at the ESC Conference 2018 and is now seeing adoption with clinical partners in European countries …See details»
BayPAT | BayPAT’s Licensee Recardio and FDA reach agreement on…
Jun 20, 2022 BayPAT’s Licensee Recardio and FDA reach agreement on Pivotal Phase 3 Regenerative Post-Myocardial Infarction Trial Design for Dutogliptin. Jun 20, 2022. ... More …See details»
Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design
June 1, 2022 — Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin along with data suggesting potential positive effects on cardiac function …See details»
Recardio’s Digital Platform, CardioCare, Rolled Out in Europe
SAN FRANCISCO, Nov. 6, 2019 /PRNewswire/ — Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that it has rolled …See details»
Recardio at BIO-EUROPE 2023
Recardio is presenting its latest advancements from its drug-based regenerative therapy clinical development program including its Phase 3 HEAL-MI study and will give a future outlook on …See details»
Recardio, Inc. (Recardio, Inc.) - 药物管线_专利_临床试验_投融营收_ …
May 7, 2025 了解Recardio, Inc. (Recardio, Inc.)公司的药物管线，治疗领域，技术平台，以及它的2项临床试验, 4篇新闻和3篇文献，技术平台:小分子化药，药物:度格列汀酒石酸盐，REC …See details»
Interim Analysis of Recardio's Phase II Clinical Trial to Be Presented ...
Jun 29, 2020 Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that the results of the interim analysis of Recardio's …See details»
Recardio and FDA Reach Agreement on Pivotal Phase 3 Trial Design
SAN FRANCISCO, June 01, 2022 (GLOBE NEWSWIRE) -- Recardio's Phase 2 trial results demonstrated the excellent safety profile of its lead drug Dutogliptin along with data …See details»